Pfizer
Pfizer head to be ABPI president
December 4, 2013Medical Communications, Sales and Marketing ABPI, MSD, PPRS, Pfizer, Whitehead, emms, khanna
The UK managing director of Pfizer Jonathan Emms is to replace Deepak Khanna as the ABPI president from April next …
Pfizer expands in Poland
December 4, 2013Sales and Marketing OTC, Pfizer, Poland, polocard, zf polpharma
Pfizer has bought the rights to one of Poland’s biggest OTC brands in a move which sees the US group …
NICE rejects Bosulif
November 28, 2013Sales and Marketing CML, NHS, NICE, Pfizer, bosulif
In a blow for Pfizer NICE has categorically rejected the manufacturer’s Bosulif as a treatment for previously-treated chronic myeloid leukaemia …
Pfizer launches another ‘medicine optimisation’ campaign
November 19, 2013Medical Communications Pfizer, RPS, npa, treatments
Patients would be more likely to follow prescriptions if they had better knowledge about the drugs they were taking according …
SMC approves Inlyta
November 13, 2013Sales and Marketing Pfizer, SMC, Sutent, inylta, rcc
Pfizer’s kidney cancer drug Inlyta has been approved by the drugs watchdog in Scotland, making it the only country in …
PPRS: thumbs-down from pharma
November 7, 2013Sales and Marketing ABPI, NHS, PPRS, Pfizer, VBP
A missed opportunity for patients, which creates financial problems for smaller companies while stifling life science investment – these are …
GSK: no Votrient Code breaches
November 4, 2013Medical Communications, Sales and Marketing GSK, PMCPA, Pfizer
Cancer drugs lift Pfizer in third quarter
October 30, 2013Sales and Marketing Lipitor, Lyrica, Pfizer, Q3, Xalkori
Pfizer saw a drop in revenue for the third quarter but the future looks bright as new products begin to …
Billions spent on European cancer care
October 15, 2013Research and Development, Sales and Marketing Cancer, Europe, Lancet, Oxford, Pfizer
A new report has shown that cancer cost the European Union a total of €126 billion in 2009, with healthcare …
Mixed tale for Pfizer psoriasis drug
October 11, 2013Sales and Marketing Enbrel, Pfizer, psoriasis, tofacitinib
Pfizer has seen its novel, oral Janus kinase (JAK) inhibitor tofacitinib turn in a mixed showing in late-stage trials in …
Manufacturing facilities news in brief
October 7, 2013Manufacturing and Production Capsugel, Fujifilm Diosynth Biotechnologies, Pfizer, Purdue Pharma, Warner Chilcott
New facilities, plant shutdowns and layoffs in the pharma manufacturing sector.
Oliver Brandicourt joins Bayer from Pfizer
September 30, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Oliver Brandicourt, Pfizer
Bayer Healthcare has appointed Pfizer’s executive Olivier Brandicourt to head up its healthcare division. Taking over from interim head Wolfgang …
NICE: final ‘no’ for Xalkori
September 25, 2013Sales and Marketing NICE, NSCLC, Pfizer, Xalkori
Pfizer’s worst fears have been confirmed today by NICE, which has rejected its new lung cancer drug Xalkori because of …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
